Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMTM tyramine challenge and multiple-dose pharmacokinetics study in healthy adults
NL-OMON51826Phase 1Completed
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hydromethylthionine mesylate in Alzheimer's disease (AD) (6 arms), sponsored by TauRx Therapeutics Ltd. Primary endpoint: Tyramine dose required to produce a 30-mmHg increase in systolic blood pressure. Started Mar 2022; status: completed.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON51826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51826.